TY  - JOUR
A1  - Bahena, Paulina
A1  - Daftarian, Narsis
A1  - Maroofian, Reza
A1  - Linares, Paola
A1  - Villalobos, Daniel
A1  - Mirrahimi, Mehraban
A1  - Rad, Aboulfazl
A1  - Doll, Julia
A1  - Hofrichter, Michaela A. H.
A1  - Koparir, Asuman
A1  - Röder, Tabea
A1  - Han, Seungbin
A1  - Sabbaghi, Hamideh
A1  - Ahmadieh, Hamid
A1  - Behboudi, Hassan
A1  - Villanueva-Mendoza, Cristina
A1  - Cortés-Gonzalez, Vianney
A1  - Zamora-Ortiz, Rocio
A1  - Kohl, Susanne
A1  - Kuehlewein, Laura
A1  - Darvish, Hossein
A1  - Alehabib, Elham
A1  - La Arenas-Sordo, Maria de Luz
A1  - Suri, Fatemeh
A1  - Vona, Barbara
A1  - Haaf, Thomas
T1  - Unraveling the genetic complexities of combined retinal dystrophy and hearing impairment
JF  - Human Genetics
N2  - Usher syndrome, the most prevalent cause of combined hereditary vision and hearing impairment, is clinically and genetically heterogeneous. Moreover, several conditions with phenotypes overlapping Usher syndrome have been described. This makes the molecular diagnosis of hereditary deaf-blindness challenging. Here, we performed exome sequencing and analysis on 7 Mexican and 52 Iranian probands with combined retinal degeneration and hearing impairment (without intellectual disability). Clinical assessment involved ophthalmological examination and hearing loss questionnaire. Usher syndrome, most frequently due to biallelic variants in MYO7A (USH1B in 16 probands), USH2A (17 probands), and ADGRV1 (USH2C in 7 probands), was diagnosed in 44 of 59 (75%) unrelated probands. Almost half of the identified variants were novel. Nine of 59 (15%) probands displayed other genetic entities with dual sensory impairment, including Alström syndrome (3 patients), cone-rod dystrophy and hearing loss 1 (2 probands), and Heimler syndrome (1 patient). Unexpected findings included one proband each with Scheie syndrome, coenzyme Q10 deficiency, and pseudoxanthoma elasticum. In four probands, including three Usher cases, dual sensory impairment was either modified/aggravated or caused by variants in distinct genes associated with retinal degeneration and/or hearing loss. The overall diagnostic yield of whole exome analysis in our deaf-blind cohort was 92%. Two (3%) probands were partially solved and only 3 (5%) remained without any molecular diagnosis. In many cases, the molecular diagnosis is important to guide genetic counseling, to support prognostic outcomes and decisions with currently available and evolving treatment modalities.
KW  - Usher syndrome
KW  - hearing impairment
KW  - combined retinal dystrophy
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-267750
SN  - 1432-1203
VL  - 141
IS  - 3-4
ER  - 
TY  - JOUR
A1  - Haertle, Larissa
A1  - Buenache, Natalia
A1  - Cuesta Hernández, Hipólito Nicolás
A1  - Simicek, Michal
A1  - Snaurova, Renata
A1  - Rapado, Inmaculada
A1  - Martinez, Nerea
A1  - López-Muñoz, Nieves
A1  - Sánchez-Pina, José María
A1  - Munawar, Umair
A1  - Han, Seungbin
A1  - Ruiz-Heredia, Yanira
A1  - Colmenares, Rafael
A1  - Gallardo, Miguel
A1  - Sanchez-Beato, Margarita
A1  - Piris, Miguel Angel
A1  - Samur, Mehmet Kemal
A1  - Munshi, Nikhil C.
A1  - Ayala, Rosa
A1  - Kortüm, Klaus Martin
A1  - Barrio, Santiago
A1  - Martínez-López, Joaquín
T1  - Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma
JF  - Cancers
N2  - For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely used, but resistance is a major obstacle to successful therapy. Several underlying mechanisms have been proposed but were only reported for a minority of resistant patients. The proteasome is a large and complex machinery. Here, we focus on the AAA ATPases of the 19S proteasome regulator (PSMC1-6) and their implication in PI resistance. As an example of cancer evolution and the acquisition of resistance, we conducted an in-depth analysis of an index patient by applying FISH, WES, and immunoglobulin-rearrangement sequencing in serial samples, starting from MGUS to newly diagnosed Multiple Myeloma to a PI-resistant relapse. The WES analysis uncovered an acquired PSMC2 Y429S mutation at the relapse after intensive bortezomib-containing therapy, which was functionally confirmed to mediate PI resistance. A meta-analysis comprising 1499 newly diagnosed and 447 progressed patients revealed a total of 36 SNVs over all six PSMC genes that were structurally accumulated in regulatory sites for activity such as the ADP/ATP binding pocket. Other alterations impact the interaction between different PSMC subunits or the intrinsic conformation of an individual subunit, consequently affecting the folding and function of the complex. Interestingly, several mutations were clustered in the central channel of the ATPase ring, where the unfolded substrates enter the 20S core. Our results indicate that PSMC SNVs play a role in PI resistance in MM.
KW  - Multiple Myeloma
KW  - drug resistance
KW  - proteasome inhibitors
KW  - immunoglobulin rearrangement
KW  - ATPase activity
KW  - PSMC2
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-305013
SN  - 2072-6694
VL  - 15
IS  - 2
ER  -